.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Sridhar Epari

Mumbai, IN

Tata Memorial Hospital

Speaker

14/09/2023
ePoster
PS6-NO-A61
Gliomas with immunohistochemical loss of MMR proteins – clinico-pathological evaluation, a tertiary care cancer institute experience
15/09/2023
13:09 – 13:15 4 Min. 2 Min.
ePoster Talk
PS6-NO-A61
Gliomas with immunohistochemical loss of MMR proteins – clinico-pathological evaluation, a tertiary care cancer institute experience

Further involvements

14/09/2023
ePoster
eP-NO-A96
POST (Preview Of Spinal Tumours) study
14/09/2023
ePoster
eP-NO-A126
Evaluation of 1p deletion by Fluorescence in situ Hybridization in meningiomas – a simple easy to implement prognostic stratifier
14/09/2023
ePoster
eP-NO-A110
MGMT gene promoter methylation in diffuse midline glioma, H3K27-mutant
14/09/2023
ePoster
PS6-NO-A63
Adult medulloblastoma – clinico-molecular spectrum, an institutional experience
14/09/2023
ePoster
PS6-NO-A61
Gliomas with immunohistochemical loss of MMR proteins – clinico-pathological evaluation, a tertiary care cancer institute experience
14/09/2023
ePoster
PS1-NO-A53
VGLL-altered CNS schwannoma is a new tumor entity with distinct DNA-methylation profile and recurrent gene fusions of either VGLL3 or VGLL1
14/09/2023
13:09 – 13:15 4 Min. 2 Min.
ePoster Talk
PS1-NO-A53
VGLL-altered CNS schwannoma is a new tumor entity with distinct DNA-methylation profile and recurrent gene fusions of either VGLL3 or VGLL1
15/09/2023
13:09 – 13:15 4 Min. 2 Min.
ePoster Talk
PS6-NO-A61
Gliomas with immunohistochemical loss of MMR proteins – clinico-pathological evaluation, a tertiary care cancer institute experience
15/09/2023
13:21 – 13:27 4 Min. 2 Min.
ePoster Talk
PS6-NO-A63
Adult medulloblastoma – clinico-molecular spectrum, an institutional experience